Market Research Blog

[345 Pages Report] As per Future Market Insights’ latest industry analysis, the global cholesterol API market was valued at around US$ 258.4 Mn in 2021 and is projected to exhibit a CAGR of 4.7% over the forecast period (2022-2032). The global market is estimated to be valued at US$ 426.9 Mn in 2032.

Liposomes are a very important part of any drug delivery system with many beneficial properties such as easy preparation, bilayer structure assembling the cellular membrane, and high biocompatibility. Extensive efforts have been dedicated to the use of cholesterol in liposome-based formulations.

Cholesterol, being an integral part of any biological membrane, plays a significant role in liposomal formulations. Liposomes with higher cholesterol content are highly stable.

According to a study by Ascension Sciences published in December 2020, parameters like stability, size, and encapsulation efficiency are used during liposome formulation. Stability of a liposome formulation is greatly influenced by the amount of cholesterol present. A higher percentage of cholesterol favors the development of larger liposomes with less encapsulation effectiveness and higher drug retention.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15406

Despite various applications of liposomes, including diagnosis, food products, gene delivery, drug & vaccine delivery, and biosensor manufacturing, their use is severely constrained by their physicochemical instability. Cholesterol plays a crucial role in the stability of a liposomal membrane.

Moreover, cholesterol affects fluidity, drug retention, phospholipid packing, transition temperature (Tm), permeability, elasticity, membrane strength, and plasma stability. Researchers are set to use cholesterol as a promising substance for the stability of liposomes.

Owing to the aforementioned factors, the global cholesterol API market is set to gain traction over the forecast period.

Key Takeaways: Cholesterol API Market

• By source, the animal-derived segment held approximately 7% of the cholesterol API market share in 2021 owing to their easy availability and low cost.
• By manufacturing process, the GMP segment is set to generate a market share of around 9% by 2032.
• By end user, the monoclonal antibodies segment is projected to grow at a CAGR of 0% during the forecast period.
• East Asia cholesterol API market is expected to showcase the highest CAGR of 6% among all other regions from 2022 to 2032.
• The U.S. cholesterol API market is anticipated to exhibit growth at a lucrative CAGR of 6% during the forecast period.

“Rising demand for RNA vaccines and monoclonal antibodies is projected to drive growth in the next decade. Besides, increasing use of liposomal formulations in drug delivery systems is set to propel sales of cholesterol APIs across the globe,” says an analyst of Future Market Insights.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15406

Competitive Landscape: Cholesterol API Market

The cholesterol API market is highly fragmented and it includes a variety of regional, start-up, and established companies. In order to increase their market share, key players are signing a large number of agreements and engaging in mergers & acquisitions, as well as collaborations.

For instance,

• In May 2021, CordenPharma and the Otto-von-Guericke-University of Magdeburg, Germany developed a scalable synthesis of pharma-grade cholesterol which is used as part of the lipid cocktail for the assembly of effective mRNA-based vaccines.
• In May 2020, Evonik announced €25m first stage of a new long-term program to support the high demand for contract manufacturing of APIs and advanced intermediates across Europe.

Get More Insights on Cholesterol API Market

Future Market Insights offers a unique perspective and actionable insights on the cholesterol API market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the source (animal-derived, plant-derived, and synthetic), manufacturing process (GMP and non-GMP), and end user (RNA vaccines, monoclonal antibodies, and others) across seven key regions of the world.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15406

Cholesterol API Market Outlook by Category

By Source:

• Animal Derived
• Plant Derived
• Synthetic

By Manufacturing Process:

• GMP
• Non – GMP

By End User:

• RNA Vaccines
• Monoclonal Antibodies
• Others

[250 Pages Report] This Peptide Receptor Radionuclide Therapy Prrt market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Peptide Receptor Radionuclide Therapy Prrt market.

Advancement and growing researches in the medical industry leads to a dramatic surge in the availability of new cancer treatment options. Radiation therapies and targeted therapy is showing significant promise in cancer treatment. For example, peptide receptor radionuclide therapy (PRRT) had recently approved the neuroendocrine tumors and projecting significant growth in the cancer treatment market. Peptide receptor radionuclide therapy (PRRT) is radioisotope or molecular therapy used to treat neuroendocrine tumors (NETs). 

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10376

Peptide receptor radionuclide therapy (PRRT) is recommended for the somatostatin receptor-positive gastroenteropancreatic NETs affected patients. Peptide receptor radionuclide therapy (PRRT) is a targeted therapy designed to slow the progression of gastroenteropancreatic NET and limiting radiation exposure to healthy tissue. Lutathera (lutetium Lu 177 Oxodotreotide) was the first drug approved for the peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In September 2017, the European Commission approved Lutathera peptide receptor radionuclide therapy (PRRT) drug manufactured by Advanced Accelerator Applications S.A. Although, the U.S. Food and Drug Administration (FDA) was approved LUTATHERA in January 2018. Growing clinical trials and development activities to create therapeutic radiopharmaceuticals expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market over the forecast period.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Drivers and Restraints-

Increasing prevalence of the neuroendocrine tumors expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. Establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT). A temporary insurance/billing code was used for the peptide receptor radionuclide therapy (PRRT) till 2018. Moreover, increasing clinical trials for the new radiopharmaceuticals drugs approval for cancer therapy expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market.

Increasing government and private organizations funding for cancer drugs and therapy development is another major factor expected to propel the growth of the peptide receptor radionuclide therapy (PRRT) market. Moreover, growing manufacturer’s interest in the radiopharmaceutical and cancer market flourish the growth of the peptide receptor radionuclide therapy (PRRT) market. Side effects such as the transient decrease in blood counts, nausea and others associated with PRRT expected to hamper the growth of the peptide receptor radionuclide therapy (PRRT) market.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-10376

Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview

Peptide receptor radionuclide therapy (PRRT) a special type of radiopharmaceutical which injected into the patients’ bloodstream. This radiopeptide travels and binds to neuroendocrine tumor cells and provide a high dose of radiation directly to the cancer cell. Big pharmaceutical market players are focusing to enter in the radiopharmaceutical market. For instance, In October 2017, Novartis AG acquired Advanced Accelerator Applications (AAA) for $3.9 billion to expand oncology portfolio. This acquisition was valuable for Lutathera radiopharmaceutical candidates which were under FDA review in 2018.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Region-wise Outlook

North America and Europe region are expected to grebe more than half of the market share for peptide receptor radionuclide therapy. Increasing clinical trials for radiopharmaceuticals and growing demand for the targeted therapy for cancer are the major factors driving the growth of the peptide receptor radionuclide therapy market in the U.S. and European countries. The Asia pacific peptide receptor radionuclide therapy market expected to grow with significant growth rate as growing demand for advance treatment option and comparatively high prevalence of cancer in India and China.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Key Market Participants

Example of some market players participants in global peptide receptor radionuclide therapy (PRRT) market find across the value chain are Advanced Accelerator Applications (AAA) (Novartis AG) and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, China ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Segmentation 

On the basis of indication, peptide receptor radionuclide therapy (PRRT) market can be segmented as:

• Foregut Neuroendocrine Tumors
• Midgut Neuroendocrine Tumors
• Hindgut Neuroendocrine Tumors

On the basis of end user, peptide receptor radionuclide therapy (PRRT) market can be segmented as:

• Hospitals
• Ambulatory Surgical Centers
• Cancer Care Centers

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-10376

Report highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The global epiglottitis treatment market demand is presently valued at around US$ 10 Billion and is forecasted to develop at a CAGR of 4.8% to reach US$ 16 Billion by 2032. Epiglottitis is a bacterial viral infection which results in inflammation and swelling of epiglottis, basically epiglottis is a cartilage structure which located at the back of the throat, beneath the tongue and the function of epiglottis is close over the trachea when foods are being swallowed, Epiglottitis causes breathing issue, tachycardia, swelling of supraglottic tissue, inspiratory stridor, pharyngitis, cervical lymph nodes, inability to handle secretion.

The symptoms of epiglottitis are drooling, dysphagia, dysphonia, distressed inspiration efforts. Differential diagnosis of adult epiglottitis includes Infectious process and non-infectious disease, infectious process symptoms are diphtheria, pertussis, croup, tracheobronchitis, peripharyngeal and others and in non-infectious disease, epiglottitis diagnosing identify by are an allergic reaction, angioneurotic, oedema, reflex laryngospasm, systemic lupus, and others.

Epiglottitis can affect people at any age, basically Epiglottitis used to diagnosed mostly in males rather than females and usually occurs in children 2 to 8 year of age, primarily epiglottitis is caused by Haemophilus influenzae type B (HIB) and other bacteria and viruses also can cause epiglottitis inflammation such as Streptococcus pneumonia, Streptococcus A, B and C, and Staphylococcus aureus.

Epiglottitis is diagnosed by the blood test to identify bacteria, x-ray, and CT scan to determine the level of swelling. Epiglottitis is treated by oxygen mask which used to deliver air to the lungs, tracheostomy which may be needed to bypass the swelling in the throat.

Epiglottitis Treatment Market: Drivers and Restraints 

Increasing prevalence and incidence rate of epiglottitis are expected to contribute to the growth of Epiglottitis Treatment market during the forecast period. HIB vaccination and third generation cephalosporin which is given by parental route (Intramuscular/intravenous) effective against Haemophilus influenzae type B which cause Epiglottitis disease is expected to enhance the growth of Epiglottitis Treatment market.

Epiglottitis is an inflammatory disease and caused by a variety of organism, so antibiotics and Combination of an intravenous antistaphylococcal agent is expected to have a significant growth during the forecast period of Epiglottitis Treatment market.

Epiglottitis Treatment drugs can sometimes cause depression and other side effects which limits the growth of Epiglottitis Treatment market. Lack of access to healthcare facilities, affordability constraints and lack of market penetration of approved drugs are the primary restraints of the Epiglottitis Treatment markets.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-8506

Epiglottitis Treatment Market: Overview 

Globally increasing prevalence of the disease expected to contribute to Epiglottitis Treatment market significantly. The global Epiglottitis Treatment market by Drug type is expected to be dominated by third generation antibiotics and

Combination of an intravenous antistaphylococcal agent. By distribution channel, Epiglottitis Treatment market is expected to be dominated by retail pharmacies. The manufacturers in the Epiglottitis Treatment market are highly focusing on the development of a new formulation for the Epiglottitis Treatment.

Epiglottitis Treatment Market: Regional Outlook 

The global Epiglottitis Treatment market is expected to be dominated by North America due to higher adoption and number of the customer using Epiglottitis Treatment and also awareness regarding Epiglottitis disease. Europe is expected to be the second most lucrative epiglottitis treatment market due to the growing number of men and also women suffering from Epiglottitis disease.

Presence of one of the fastest growing economies such as India and China further expected to drive the growth of Epiglottitis Treatment market in the APAC region. Latin America Epiglottitis Treatment market is expected to witness steady growth due to increased diagnosis of the condition in the region.

The Middle East and Africa Epiglottitis Treatment is expected to be the least lucrative market due to low treatment seeking rate, low product penetration, and low diagnosis rate. Overall, global Epiglottitis Treatment market expected to witness significant growth due to increasing penetration of products and diagnosis.

Epiglottitis Treatment Market: Key Players 

Examples of some of the market participants in the global Epiglottitis Treatment market identified are Abbott, Merck & Co., Inc, AstraZeneca, Boehringer Ingelheim International GmbH, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Johnson & Johnson, Roche Holding AG, and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Epiglottitis Treatment Market: Segmentation 

Global Epiglottitis Treatment market is segmented on the basis of Drug, Route of administration, by Distribution Channel and by region

Based on the Drug, Epiglottitis Treatment market is segmented as: 

• Broad-spectrum antibiotic
• Targeted antibiotic
• Steroid medication

Based on the Route of administration, Epiglottitis Treatment market is segmented as: 

• Oral
• Parental

Based on the end user Epiglottitis Treatment market is segmented as: 

• Hospitals Pharmacies

• Retail Pharmacies
• Drug Stores
• Clinics
• Online Pharmacies

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-8506

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

1. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

1. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

Inquire Before Buying This Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-8506

1. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

1. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Mn) Analysis By Drug, 2017-2021

5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug, 2022-2032

5.3.1. Broad-spectrum Antibiotic

5.3.2. Targeted Antibiotic

5.3.3. Steroid Medication

5.4. Y-o-Y Growth Trend Analysis By Drug, 2017-2021

5.5. Absolute $ Opportunity Analysis By Drug, 2022-2032

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

[250 Pages Report] The global IVD antibodies market is expected to grow at a healthy CAGR of around 7% between 2022 and 2032, reaching a valuation of nearly US$ 77 billion by 2027. The rising prevalence of chronic and infectious diseases worldwide, as well as the increasing need for early diagnosis of chronic diseases in order to initiate proper treatment, are driving demand for IVD antibodies.

Report Attribute	Details
IVD Antibodies Market Estimated Growth Rate (2022-2032)	7% CAGR
IVD Antibodies Market Projected Size (2027)	US$ 77 Bn

In vitro diagnostics tests are used in laboratories, healthcare settings or directly by consumers at home for the detection of various diseases, infections and other medical conditions. Various companies in the IVD antibodies market are focusing on mergers and acquisitions with regional players. For example, in Sep. 2018, Summa Equity AB acquired Turku-based HyTest Ltd. whose regional presence in the U.S. and Asia is good. Continuously evolving nature of IVD antibodies market further expected to get maximum traction. Superior capability of the IVD antibodies to detect complex diseases such as cancer and use of IVD antibodies in therapeutic monitoring, evaluating blood safety before transfusion further makes it preferred choice of diagnosis test.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8565
IVD Antibodies Market: Drivers and RestraintsIncreasing incidence of chronic diseases such as HIV, hepatitis, cancer, cardiovascular diseases, etc. expected to drive the growth of IVD antibodies market. Incidence of cancer and cardiovascular diseases is increasing rapidly and hence aging population of world further expected to drive the growth of IVD antibodies market. The ease of use of IVD antibodies for the diagnosis at laboratories, hospitals or even at home further increases patient compliance and makes IVD antibodies preferred choice.

The IVD antibodies market is further driven by increasing research and development funding which in turn improving the outcome of diagnostic tests as well as manufacturing of high end quality IVD antibodies for assays. Manufacturers in the IVD antibodies market are focusing on mergers, acquisitions, collaborations and agreements such as Sebia Inc. one of the major IVD manufacturing company signed an agreement with Janssen Biotech to develop multiple myeloma IVD test. Whereas, low product penetration and higher cost of the IVD antibodies may hamper the potential growth of the market. Although manufacturers are focusing on developing novel IVD antibodies for diagnosis of different diseases but time consuming nature of research and development and tedious product approval process may hamper the growth of market.

IVD Antibodies Market: Overview

The global IVD antibodies market is majorly driven by the increasing chronic disease incidence as well as increasing product penetration in the low and middle income countries. By product type, IVD antibodies market is expected to be dominated by the tumor markers due to high adoption for the diagnosis of malignancies. By the application, the IVD antibodies market is dominated by the cancer due to high number of diagnostic procedures. By end user, IVD antibodies market is dominated by the diagnostic laboratories due to high patient footfall for the disease diagnosis. The increasing R & D expenditure by leading biopharmaceutical companies for the development and evaluation of IVD antibodies for different diagnosis of various diseases expected to impact the market significantly.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8565

IVD Antibodies Market: Regional Outlook

The global IVD antibodies market is dominated by North America due to higher product penetration. Europe is expected to be the second most lucrative IVD antibodies market due to higher number of diagnostic procedure and favorable reimbursement scenario. Latin America is expected to experience steady market growth due to increasing IVD antibodies adoption for the diagnostic procedures. Asia-Pacific is emerging market in IVD antibodies due to rapidly increasing product penetration, and emerging countries such India and China where healthcare infrastructure evolving rapidly. Middle East and Africa is expected to be least revenue generating IVD antibodies market due to low product penetration as well as limited availability of good healthcare infrastructure in most of the MEA region.

IVD Antibodies Market: Key Players

The key market participants operating in the IVD antibodies market are: Abcam plc., Thermo Fisher Scientific, Rockland Immunochemicals Inc., GenScript, Bio-Rad Laboratories, Inc., SDIX, LLC., Advy Chemical Pvt. Ltd., MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., HyTest Ltd., Abbott and Others

The research report presents a comprehensive assessment of the IVD Antibodies market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to IVD Antibodies market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

• IVD Antibodies Market Segments
• IVD Antibodies Market Dynamics
• IVD Antibodies Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/8565

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

IVD Antibodies Market: Segmentation

The global IVD antibodies market is segmented based on the product type, application, end user and region

By product type IVD antibodies market is segmented as:

• Cardiac Markers
• Tumor Markers
• Kidney Injury Markers
• Infection and Inflammation Antibodies

By application, IVD antibodies market is segmented as:

• Immunology
• Cancer
• Cardiovascular Diseases

By end user IVD antibodies market is segmented as:

• Hospitals
• Diagnostic Laboratories
• Homecare settings
• Others

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[307 Pages Report] The global weight management market is expected to secure US$ 725.6 Billion while recording a CAGR of 7.7% during the forecast period from 2022 to 2032, according to a recently published market research report by Future Market Insights. Increasing adoption of a sedentary lifestyle is expected to drive the global weight management market.

As per the Institute of Health Metric and Evaluation, 30% of the world’s population is obese. Obese is one of the major health challenges in developed and developing countries. Also, the rising volume of bariatric surgeries and rising adoption of online weight loss & management programs are anticipated to positively influence the industry in forecast period.

Weight Management Market CAGR (2022-2032)	7.7%
Weight Management Market (2022)	US$ 345.5 Billion
Weight Management Market (2032)	US$ 725.6 Billion

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15092

The growing prevalence of obesity among the expanding population is expected to propel the market expansion during the forecast period. As per the World Obesity Atlas 2022, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. This significant rise in the number of obese patients is anticipated to drive demand for an efficient weight management system. Further, growing awareness about weight management and obesity among developing nations is expected to drive market growth in the coming period.

Increasing strategic collaborations of players with each other are expected to drive market growth during the forecast period. In September 2019, Currax Pharmaceutical disclosed the acquisition of Nalpropion Pharmaceuticals. This acquisition resulted in the addition of Contrave anti-obesity medication to Currax’s product portfolio. Similarly, in November 2019, Novo Nordisk collaborated with UNICEF to prevent children from obesity. Such partnerships among players are expected to benefit the industry growth during the forecast period.

Lack of awareness regarding obesity and the inability to afford premium health club memberships among developing countries are expected to impact the market negatively in the forthcoming period. As per IQVIA, only 2% of the total obese population is treated with prescribed medicines. Further, the presence of a limited number of market players is another cause hindering the expansion. However, rising disposable income and increasing awareness about the alternatives for weight loss and management can propel market growth in the forecast period.

Key Takeaways from the Market Study

• Weight management market to secure US$ 725.6 Billion during the forecast period from 2022-to 2032.
• By equipment, the fitness equipment segment is anticipated to expand at a CAGR of 7.6% during the forecast period.
• The weight management market to be dominated by the U.S while garnering US$ 250 Billion by 2032
• Weight management industry in China is expected to expand at the highest CAGR of 6.8% during the forecast period
• Weight management market in Japan is estimated to reach US$ 41.1 Billion by 2032

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15092

“Increasing cases of obesity and the growing health concerns among baby boomers are expected to support the market expansion in the coming time,” remarks an analyst at FMI.

Competition Analysis

Key players in the industry include Herbalife Nutrition Ltd., NutriSystem, Inc., Weight Watchers International, Inc., eDiets.com, Inc., and Brunswick Corporation. Major developments in the market are:

• In June 2022, Herbalife Nutrition, inked a sports nutrition partnership with Notre Dame shooting guard Blake Wesley, who has been training at the Herbalife Nutrition IMPACT Basketball Center.
• In January 2021, Herbalife Nutrition, an eminent nutrition company, announced that it had inked an agreement to repurchase approximately US$ 600 million of the Company’s common share beneficially owned by Carl C. Icahn and certain of his affiliates at a price of US$ 48/05 per share.
• In December 2020, Kainos Capital, a firm focused on specializing in managing food and consumer businesses, completed the acquisition of Nutrisystem from Tivity Health for US$ 575 Million. The private Capital Group of MSD Partners, LP partnered with Kainos Capital in the transaction in form of preferred and common equity investment.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global weight management market, presenting a historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Diet (Meals, Beverages, Supplements), Equipment (Fitness Equipment, Surgical Equipment), Services (Fitness Centers, Slimming Centers, Consultation Services, Online Weight Loss Services), & Region(North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15092

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

Key Segments Profiled in the Global Weight Management Market Report

Global Weight Management Market by Diet:

• Weight Management Meals
• Weight Management Beverages
• Weight Management Supplements

Global Weight Management Market by Equipment:

• Weight Management Fitness Equipment
• Weight Management Surgical Equipment

Global Weight Management Market by Services:

• Weight Management across Fitness Centers
• Weight Management across Slimming Centers
• Weight Management Consultation Services
• Weight Management through Online Weight Loss Services

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[300 Pages Report] The global HIV antivirals market is expected to be worth $30.6 billion in 2022, with a CAGR of 4.4 percent during the forecast period (2022-2032). According to a recent study, fixed-dose combinations (FDCs) will account for more than 83 percent of the HIV antivirals market in 2021.

According to Future Market Insights, the global HIV antivirals market was around US$ 29.4 Bn in 2021 and is expected to exhibit a CAGR of close to 4.4% over the forecast period (2022-2032).

The demand for HIV antivirals is increasing due to growing prevalence of HIV across the globe. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 37.7 million people were infected with HIV in the world in 2020.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15095

Market Outlook:

Data Points	Market Insights
HIV Antivirals Market Value 2021dg	US$ 29.4 Bn
Market Value 2022	US$ 30.6 Bn
Market Value 2032	US$ 47.0 Bn
CAGR 2022-2032	4.4%
Market Share of Top 5 Countries	64.8%

Further, demand for HIV antivirals will also surge amid surging rate of unprotected sex and the use of contaminated needles or syringes. As per the National Youth Risk Behavior Survey provided by the Centers for Disease Control and Prevention (CDC), 38% of the respondents had sexual intercourse, and 9% had four or more sexual partners in the U.S., during high school, in 2019.

Hence, key players are developing generic anti-HIV drugs at cost-effective prices to capitalize on growing demand. For instance, generic versions of Lamivudine, Abacavir, and Efavirenz are available in the U.S. at prices lower than their branded versions. This is expected to create lucrative opportunity for the generic HIV antivirals manufacturers to provide affordable medical facilities in low and middle-income countries.

Key Takeaways from Market Study

• Fixed-dose combinations (FDCs) segment held over 83.2% market value share in 2021, owing to their ability to improve adherence to an HIV treatment regimen.
• Hospital pharmacies are the leading sales channel of the HIV antivirals, with over 53% of the market share in 2021, and are anticipated to grow at a CAGR rate of 4. 5% in upcoming decade
• North America is expected to dominate the global HIV antivirals market, holding a share of 38.7% in 2021.
• India is expected to lead the growth in South Asia market owing to the growing cases of HIV in the country

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15095

“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.

Market Competition

Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:

• In October 2021, Merck announced favorable results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed-dose combination pill of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection.
• In March 2021, Gilead announced the development and commercialization of long-acting, investigational treatment combinations of Lenacapavir and Islatravir in HIV in association with Merck.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the HIV antiviral market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (fixed-dose combinations (FDCs), integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry inhibitors – CCR5 co-receptor antagonist, protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and others), by sales channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven key regions of the world.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15095

Key Players :

• ViiV Healthcare
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• Genetech, Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie
• Cipla
• Pfizer Inc.
• Mylan N.V.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Macleods Pharmaceuticals Ltd
• Emcure Pharmaceuticals Limited
• Aspen Pharmacare Limited
• Lupin Ltd.
• Sun Pharmaceutical Industries Ltd.
• Theratechnologies Inc.
• Strides Arcolab Limited
• Hetero labs limited
• Laurus Laboratories Ltd

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

• Fixed Dose Combinations (FDCs)
• Integrase Strand Transfer Inhibitors (INSTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors – CCR5 co-receptor antagonist
• Protease Inhibitors (PIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies